Advertisement

Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 μg

  • L. M. Koeth
  • E. Matuschek
  • G. Kahlmeter
  • G. Stone
Original Article

Abstract

Ceftazidime-avibactam disk studies were performed for disk mass selection and for establishing EUCAST quality control ranges and zone diameter breakpoints. The disk mass study included disk diffusion testing with ceftazidime-avibactam 10-4 and 10-6 μg disks and broth microdilution MIC testing for challenge set of 94 Enterobacteriaceae and 45 Pseudomonas aeruginosa. EUCAST SOP 9.0-based QC and MIC-disk correlations studies were followed for development of ceftazidime-avibactam 10-4 μg ranges for Escherichia coli ATCC 25922, P. aeruginosa ATCC 27583, and Klebsiella pneumoniae ATCC 700603 and for zone diameter breakpoint determination. The ceftazidime-avibactam 10-4 and 10-6 μg disks performed similar in comparison to broth microdilution, with zones ≤ 14 mm for all resistant strains. The 10-4 μg disk was selected and used in QC and breakpoint studies. There was minimal variation of ceftazidime-avibactam 10-4 μg QC study results between disks, media, and sites. The QC ranges were within 7 mm for all strains. The zone diameter breakpoint study demonstrated good correlation of MIC and disk results. The established zone diameter breakpoints resulted in false susceptible rates of 1.6 and 4.0% for Enterobacteriaceae and P. aeruginosa. EUCAST selected the ceftazidime-avibactam 10-4 μg disk and established QC ranges for E. coli 25922 of 24–30 mm, P. aeruginosa ATCC 27853 of 21–27 mm, and K. pneumoniae ATCC 700603 of 18–24 mm. The zone diameter breakpoints that correlated best with the MIC breakpoints of susceptible ≤ 8 mg/L and resistant > 8 mg/L were Enterobacteriaceae (S ≥ 13, R < 13 mm) and P. aeruginosa (S ≥ 17, R < 17 mm).

Notes

Acknowledgements

The following investigators and laboratories are recognized for participation in the validation of the quality control ranges and clinical isolates: Andreas Petersen, Statens Serum Institut, Copenhagen, Denmark; Karen Bowker, Southmead Hospital, Bristol, UK; Annarita Mazzariol, Dipartimento di Patologia e Diagnostica, Verona, Italy; Christiane Müllner, analyse BioLab GmbH, Linz, Austria; Maria García-Castillo and Marta Tato Diez, Hospital Universitario Ramón y Cajal, Madrid, Spain; Mandy Wootton, University Hospital of Wales, Cardiff, UK; and Stina Bengtsson, Clinical Microbiology, Central Hospital, Växjö, Sweden.

Funding

This study was funded by AstraZeneca Pharmaceuticals LP. AstraZeneca’s rights to ceftazidime-avibactam were acquired by Pfizer in December 2016.

Compliance with ethical standards

Conflict of interest

Gregory Stone was an employee of AstraZeneca and is a current employee of Pfizer. The other authors declare that they have no conflict of interest.

References

  1. 1.
    The European Committee on Antimicrobial Susceptibility Testing. EUCAST Disk Diffusion Test Manual. v 4.0, 2014. http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/
  2. 2.
    The International Standards Organization. Clinical laboratory testing and in vitro diagnostic test systems—susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO/FDIS 20776-1:2006 http://www.iso.org/iso/catalogue_detail.htm?csnumber=41630
  3. 3.
    The European Committee on Antimicrobial Susceptibility Testing. Procedure for establishing zone diameter breakpoints and quality control criteria for new antimicrobial agents. EUCAST Standard Operating Procedure 9.0, November, 2014. http://www.eucast.org/documents/sops/
  4. 4.
    Berkhout J, Melchers MJ, van Mil AC, Nichols WW, Mouton JW (2015) In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother 59(2):1138–1144CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Clinical Laboratory and Standards Institute (2015) Performance standards for antimicrobial disk susceptibility tests, 11th ed. Approved Standard M02-A12. CLSI, Wayne, PAGoogle Scholar
  6. 6.
    Clinical Laboratory and Standards Institute (2017) Performance standards for antimicrobial susceptibility testing, 27th ed. Approved standard, CLSI publication M100-S27. Clinical Laboratory and Standards Institute, Wayne, PA 2013Google Scholar
  7. 7.
    Koeth LM, DiFranco-Fisher JM, Scangarella-Oman NE, Miller LA (2017) Analysis of MIC and disk diffusion testing variables for gepotidacin and comparator agents against select bacterial pathogens. J Clin Microbiol 55(6):1767–1777CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP (2007) Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 45(10):3151–3154CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jacobs MR, Bajaksouzian S, Windau A, Appelbaum PC, Lin G, Felmingham D, Dencer C, Koeth L, Singer ME, Good CE (2002) Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae. J Clin Microbiol 40(9):3269–3276CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Daly JS, Dodge RA, Glew RH, Soja DT, DeLuca BA, Hebert S (1997) Effect of zinc concentration in Mueller-Hinton agar on susceptibility of Pseudomonas aeruginosa to imipenem. J Clin Microbiol 35(4):1027–1029PubMedPubMedCentralGoogle Scholar
  11. 11.
    Nilius AM, Beyer JM, Flamm RK, Tanaka SK (1997) Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. J Clin Microbiol 35(6):1311–1315PubMedPubMedCentralGoogle Scholar
  12. 12.
    Washington JA 2nd, Snyder RJ, Kohner PC, Wiltse CG, Ilstrup DM, McCall JT (1978) Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa. J Infect Dis 137(2):103–111CrossRefPubMedGoogle Scholar
  13. 13.
    The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, 2017. http://www.eucast.org/clinical_breakpoints/

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory Specialists, IncWestlakeUSA
  2. 2.EUCAST Development LaboratoryVäxjöSweden
  3. 3.Pfizer, IncGrotonUSA

Personalised recommendations